AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a filing showed on Tuesday.

Reuters • 13 hours ago

AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?

AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.

Zacks Investment Research • Feb 20, 2026

Top 3 Health Care Stocks That May Collapse This Quarter

As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Feb 18, 2026

Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors

Impax International Sustainable Economy Fund portfolio marginally underperformed MSCI EAFE benchmark, driven primarily by stock-specific effects and style tilts. AstraZeneca's stock has an attractive Sustainability Lens profile with opportunities in Health Care Access & Innovation and Wellbeing. RELX's stock has a high Corporate Resilience score due primarily to environmental and social risk management practices.

Seeking Alpha • Feb 18, 2026

Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory

Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings trajectory as the drugmaker prioritises revenue growth through escalating research spending. The broker warns the current valuation looks full at 20 times forecast 2026 earnings despite confidence the company can exceed its $80 billion 2030 revenue target.

Proactive Investors • Feb 13, 2026

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.

MarketBeat • Feb 12, 2026

Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline

Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at Citi following full-year results and 2026 guidance that the bank described as “reassuring”, with a reiterated target price of £170 and unchanged earnings forecasts. Management confirmed expectations for low double-digit earnings growth in 2026, aligning with consensus, while the medium single- to high single-digit revenue outlook was ahead of market forecasts.

Proactive Investors • Feb 11, 2026

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. During its fifth year, AstraZeneca's ACT on Health Equity initiative will fund 47 nonprofit programs whose missions support the goal of ad.

Business Wire • Feb 11, 2026

AstraZeneca profit climbs on cancer and heart drug demand

The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Market Watch • Feb 10, 2026

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.

Reuters • Feb 10, 2026